Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: PERERA
Liczba odnalezionych rekordów: 3



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku

1/3

Tytuł oryginału: Conference on molecular epidemiology in preventive medicine - achievements and new challenges.
Opracowanie edytorskie: Jędrychowski Wiesław (Ed.), Perera Frederica [P.] (ed.), Maugeri Umberto (ed.).
Źródło: Prz. Epidemiol. 2002: 56 supl.: Conference on molecular epidemiology in preventive medicine - achievements and new challenges s.[1-8], 1-393, il., tab., bibliogr. [przy ref.] - Konferencja pt. Molekularna epidemiologia w medycynie prewencyjnej - osiągnięcia i nowe wyzwania Kraków 20-22.06. 2002
Sygnatura GBL: 301,250

Typ dokumentu:
  • praca związana ze zjazdem
  • streszczenie


    2/3

    Tytuł oryginału: Molecular epidemiology in preventive medicine - rationale and expectations.
    Autorzy: Jędrychowski Wiesław A., Perera Frederica P.
    Źródło: Prz. Epidemiol. 2002: 56 supl.: Conference on molecular epidemiology in preventive medicine - achievements and new challenges s.3-18, il., tab., bibliogr. 33 poz. - Konferencja pt. Molekularna epidemiologia w medycynie prewencyjnej - osiągnięcia i nowe wyzwania Kraków 20-22.06. 2002
    Sygnatura GBL: 301,250

    Typ dokumentu:
  • praca związana ze zjazdem
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: There are four major for with biomarkers may be used in epidemiological research: (1) to improve the assessment of exposure; (2) to identify subgroups of persons of different susceptibility to the effects of the exposure; (3) to measure early health outcome with some predictive significance; and (4) to differentiate disease subtypes with potentially different aetiologies. The least explored in epidemiological research is early health outcome measures to predict the occurence of clinical disease and to elucidate the biological mechanism of pathogenesis. This use is conceptually more complex than rather simple and the well-estabilished use of biomarkers to improve exposure assessment or to study interindividual variations in disease susceptibility. In principle, this form of use could accelerate or otherwise facilitate etiological research. For the etiologic studies biomarkers should (1) be on the causal pathway, (2) have a high probability of progression to clinical disease, and (3) account for all or most of the cases of the specified clinical outcome. Such biomarkers would be useful provided they presented a long lead-time relative to clinical disease occurrence. Biomarkers with good predictivity of a disease may be used for: (1) screening for pre-clinical disease; (2) enhancement of conventional epidemiological studies of diseases aectiology; (3) monitoring for variation or change in population health risk ; and (4) evaluation and monitoring of primary prevention measures.


    3/3

    Tytuł oryginału: Molecular epidemiology in cancer prevention.
    Autorzy: Perera Frederica P.
    Źródło: Prz. Epidemiol. 2002: 56 supl.: Conference on molecular epidemiology in preventive medicine - achievements and new challenges s.29-48, bibliogr. 136 poz. - Konferencja pt. Molekularna epidemiologia w medycynie prewencyjnej - osiągnięcia i nowe wyzwania Kraków 20-22.06. 2002
    Sygnatura GBL: 301,250

    Hasła klasyfikacyjne GBL:
  • onkologia

    Typ dokumentu:
  • praca związana ze zjazdem
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Cancer prevention has been the stated goal of molecular cancer epidemiology for the past 17 years; and much has been written about its promise and potential. Using the exampples of four well studied environmentall carcinogens - tobacco smoke, polycyclic aromatic hydrocarbons, aflatoxin B1, and benzene - and their role in lung, breast, liver cancer and leukemia, we can trace the progress of molecular epidemiology, asking "How far have we come toward the goal of prevention?" This review demonstrates that molecular epidemiology has made important contributions in identifying causal factors in cancer, in documenting the major role of individual susceptibility in risk from environmental carcinogens, and in developing new interventions. In particular, the research has underscored the importance of focusing interventions (regulations, public education programs, health surveillance, behavior modification programs, and chemoprevention strategies) on subgroups at greatest risk as a result of genetic and/or acquired susceptibility. But the translation of research to risk assessment and preventive health policy has not yet happened in a meaningful way. Thus a priority is the incorporation of existing scientific data on differential susceptibility into risk assessment and the creation of an infrastructure to further this process by linkings scientists, policymakers, and other constituencies.

    stosując format: